International Journal of Dermatology

Texto completo: acesso restrito. p. 203–207 Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-01-13T13:41:46Z No. of bitstreams: 1 André Báfica.pdf: 242239 bytes, checksum: 11179b434c51c965c7444dc03b6fe533 (MD5) Approved for entry into archive by Flávia Ferreira (flaviaccf@yahoo.com.br) on 2014-11-28T15:40:33Z (GMT) No. of bitstreams: 1 André Báfica.pdf: 242239 bytes, checksum: 11179b434c51c965c7444dc03b6fe533 (MD5) Made available in DSpace on 2014-11-28T15:40:33Z (GMT). No. of bitstreams: 1 André Báfica.pdf: 242239 bytes, checksum: 11179b434c51c965c7444dc03b6fe533 (MD5) Previous issue date: 2003 Background American cutaneous leishmaniasis is characterized by single or multiple ulcerations. Cytokines, among other factors, have been shown to influence lesion development and tumoral necrosis factor-alpha is a major cytokine implicated in pathogenesis of ulcers. Observations We tested oral pentoxifylline, a known tumoral necrosis factor-alpha inhibitor, at doses of 400 mg (2–3x/day), associated to N-methylglucamine antimoniate (15 mg/kg/day) in two patients with American cutaneous leishmaniasis unresponsive to antimonial drugs. We observed a satisfactory response with quick cure of skin lesions of these patients. Conclusions Our results suggest that oral pentoxifylline in association to N-methylglucamine antimoniate should be consider in refractory cutaneous leishmaniasis patients.